# NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT06919666** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 29 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** NT219

## Key facts

- **NCT ID:** NCT06919666
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2030-02
- **Final completion:** 2031-02
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919666, "NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06919666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*